Tag: IRC § 162(a)

  • Mylan, Inc. & Subsidiaries v. Commissioner, 156 T.C. No. 10 (2021): Deductibility of Legal Expenses in Pharmaceutical Patent Litigation

    Mylan, Inc. & Subsidiaries v. Commissioner, 156 T. C. No. 10 (2021)

    In a landmark ruling, the U. S. Tax Court held that Mylan, a generic drug manufacturer, must capitalize legal expenses related to preparing FDA-required notice letters for generic drug applications, while expenses defending against patent infringement suits are deductible. This decision clarifies the tax treatment of legal costs incurred by generic drug companies in navigating the complex regulatory landscape of pharmaceutical patents, impacting how such costs are managed in the industry.

    Parties

    Mylan, Inc. & Subsidiaries, the petitioner, is a U. S. corporation engaged in the manufacture of both brand name and generic pharmaceutical drugs. The respondent, the Commissioner of Internal Revenue, represents the Internal Revenue Service (IRS). Mylan challenged the IRS’s disallowance of deductions for legal expenses incurred during 2012, 2013, and 2014.

    Facts

    Mylan incurred significant legal expenses from 2012 to 2014 related to its efforts to bring generic versions of brand name drugs to market. The process involved submitting Abbreviated New Drug Applications (ANDAs) to the Food & Drug Administration (FDA), which required certifications regarding any patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) that covered the brand name drugs. Mylan often certified that these patents were invalid or would not be infringed by their generic drugs (paragraph IV certifications), triggering the need to send notice letters to the brand name drug manufacturers and patentees. These certifications also constituted an act of patent infringement, leading to lawsuits against Mylan under 35 U. S. C. § 271(e)(2). Mylan deducted the legal fees incurred for preparing notice letters and defending against these infringement suits as ordinary and necessary business expenses under Internal Revenue Code (IRC) § 162(a). The IRS, however, determined these were nondeductible capital expenditures under IRC § 263(a).

    Procedural History

    Upon examination of Mylan’s 2012, 2013, and 2014 tax returns, the IRS disallowed the deductions for legal expenses, asserting they were capital expenditures to be amortized over 15 years under IRC § 197. The IRS issued notices of deficiency for each year, determining tax deficiencies of $16,430,947, $12,618,695, and $20,988,657, respectively. Mylan petitioned the U. S. Tax Court for redetermination, and the cases were consolidated for trial. The Tax Court’s standard of review was de novo.

    Issue(s)

    Whether the legal expenses incurred by Mylan to prepare notice letters required for FDA approval of generic drugs are required to be capitalized under IRC § 263(a)?

    Whether the legal expenses incurred by Mylan to defend against patent infringement suits under 35 U. S. C. § 271(e)(2) are deductible as ordinary and necessary business expenses under IRC § 162(a)?

    Rule(s) of Law

    IRC § 162(a) allows a deduction for “all the ordinary and necessary expenses paid or incurred during the taxable year in carrying on any trade or business. ” Conversely, IRC § 263(a) mandates the capitalization of expenditures that create or enhance a separate and distinct asset or generate significant future benefits. The regulations under IRC § 1. 263(a)-4(b)(1) require the capitalization of amounts paid to acquire or create certain intangibles, including rights obtained from a governmental agency. The origin of the claim test, established in cases such as Woodward v. Commissioner, 397 U. S. 572 (1970), is used to determine whether legal expenses are deductible or must be capitalized based on the nature of the underlying claim.

    Holding

    The Tax Court held that the legal expenses incurred by Mylan to prepare notice letters required for FDA approval are capital expenditures under IRC § 263(a) because they facilitate the acquisition of FDA approval, an intangible asset. Conversely, the legal expenses incurred by Mylan to defend against patent infringement suits under 35 U. S. C. § 271(e)(2) are deductible as ordinary and necessary business expenses under IRC § 162(a) because such litigation is distinct from the FDA approval process and arises from the protection of business profits.

    Reasoning

    The court’s reasoning hinged on the distinction between the two types of legal expenses. For notice letter expenses, the court applied the rule that amounts paid to facilitate the acquisition of an intangible asset must be capitalized. The court found that the notice letters were a required step in securing FDA approval, thus facilitating the acquisition of the intangible right to market the generic drug. The court rejected Mylan’s argument that these expenses were merely related to potential patent litigation, emphasizing that the notice was a statutory prerequisite for ANDA approval.

    Regarding the litigation expenses, the court applied the origin of the claim test and found that these expenses arose out of patent infringement claims, which are torts aimed at protecting the patent holder’s business profits. The court relied on precedents such as Urquhart v. Commissioner, 215 F. 2d 17 (3d Cir. 1954), which established that expenses incurred in defending patent infringement suits are deductible because they relate to the protection of business profits rather than the acquisition of property rights. The court distinguished these expenses from those incurred in defending title to intellectual property, which are capital expenditures.

    The court also considered regulatory examples under IRC §§ 1. 263(a)-4 and 1. 263(a)-5, finding that the litigation expenses did not facilitate the acquisition of FDA approval but were instead related to resolving patent rights, thus supporting their deductibility.

    Disposition

    The court sustained the IRS’s determination to capitalize the legal expenses incurred for preparing notice letters and upheld the disallowance of deductions for those expenses. Conversely, the court allowed deductions for the legal expenses incurred in defending patent infringement suits. The court’s decisions will be entered under Rule 155 of the Tax Court Rules of Practice and Procedure.

    Significance/Impact

    This decision has significant implications for the pharmaceutical industry, particularly for generic drug manufacturers. It clarifies that legal expenses related to the regulatory process of obtaining FDA approval must be capitalized, affecting the timing of tax deductions for such costs. Conversely, it affirms the deductibility of expenses incurred in defending against patent infringement suits, providing clarity and potential tax benefits for companies engaged in such litigation. The ruling may influence how generic drug companies structure their legal strategies and manage their tax liabilities, potentially affecting the pace and cost of bringing generic drugs to market. The case also underscores the importance of the origin of the claim test in distinguishing between deductible and capital expenditures in the context of legal fees.

  • National Starch & Chemical Corp. v. Commissioner, 93 T.C. 67 (1989): When Takeover Expenses Are Capitalized

    National Starch & Chemical Corp. v. Commissioner, 93 T. C. 67 (1989)

    Expenses incurred by an acquired company in a friendly takeover are capital expenditures, not deductible as current expenses under IRC § 162(a).

    Summary

    National Starch & Chemical Corp. sought to deduct expenses related to its acquisition by Unilever, including legal and investment banking fees. The Tax Court held that these expenses were capital in nature because they were incurred to facilitate a long-term shift in corporate ownership, expected to benefit the company over many future years. This ruling emphasized that the dominant aspect of the expenditures was the takeover itself, not the incidental fiduciary duties of the directors. The decision clarified that such expenses do not qualify as ordinary and necessary under IRC § 162(a), impacting how similar corporate transactions are treated for tax purposes.

    Facts

    National Starch & Chemical Corp. (National Starch) was acquired by Unilever United States, Inc. (Unilever U. S. ) in a friendly takeover. In the transaction, National Starch’s shareholders either exchanged their stock for cash or for nonvoting preferred stock in a newly formed Unilever subsidiary. National Starch incurred significant expenses, including legal fees from Debevoise, Plimpton, Lyons & Gates and investment banking fees from Morgan Stanley & Co. Inc. These fees were incurred to structure the transaction, obtain a fairness opinion, and ensure compliance with fiduciary duties to shareholders. National Starch attempted to deduct these expenses as ordinary and necessary business expenses under IRC § 162(a).

    Procedural History

    The Commissioner of Internal Revenue disallowed the deduction of these expenses, leading National Starch to petition the U. S. Tax Court. The Tax Court considered whether the expenses were deductible under IRC § 162(a) or if they should be treated as non-deductible capital expenditures.

    Issue(s)

    1. Whether the expenses incurred by National Starch incident to its acquisition by Unilever are deductible as ordinary and necessary business expenses under IRC § 162(a).

    Holding

    1. No, because the expenses were capital in nature, incurred to effect a long-term shift in corporate ownership that was expected to produce future benefits for the company.

    Court’s Reasoning

    The Tax Court applied the principle that expenditures leading to benefits that extend beyond the current tax year are capital in nature. The court found that the expenses incurred by National Starch were related to a significant shift in corporate ownership, which was deemed to be in the long-term interest of the company. The court rejected the argument that these expenses were deductible because they did not result in the creation or enhancement of a separate asset, emphasizing instead that the dominant aspect of the transaction was the takeover itself. The court cited several cases to support its view that expenditures related to corporate reorganizations, mergers, or shifts in ownership are capital expenditures, even if they do not result in the acquisition of a tangible asset. The court also noted that the expectation of future benefits, even if not immediately realized, was sufficient to classify the expenses as capital.

    Practical Implications

    This decision has significant implications for how companies should treat expenses related to corporate acquisitions. It establishes that expenses incurred by an acquired company in facilitating a takeover are not deductible as ordinary business expenses but must be capitalized. This ruling affects tax planning for corporate transactions, requiring companies to account for such expenses as part of their capital structure rather than as immediate deductions. The decision also impacts how legal and financial advisors structure and advise on corporate takeovers, emphasizing the need to consider the long-term benefits of the transaction when determining the tax treatment of related expenses. Subsequent cases have followed this precedent, further solidifying the principle that takeover expenses by the acquired entity are capital in nature.

  • Poirier v. Commissioner, 54 T.C. 1215 (1970): Deductibility of Job Search Expenses for Continuing in Same Trade or Business

    Poirier v. Commissioner, 54 T. C. 1215 (1970)

    Job search expenses are deductible under IRC § 162(a) as ordinary and necessary expenses when incurred to continue in the same trade or business, even if the new job is not ultimately accepted.

    Summary

    In Poirier v. Commissioner, the Tax Court ruled that job search expenses paid to a placement agency are deductible as ordinary and necessary business expenses under IRC § 162(a). The petitioner, an engineer, paid fees to Chusid to secure new employment but ultimately stayed with his old employer after receiving a promotion. The court held that these expenses were deductible because they were incurred to maintain his trade or business as an engineer, following precedent set in Primuth and Motto.

    Facts

    The petitioner, an engineer employed by General Electric, paid Chusid $1,781. 75 for job search services. With Chusid’s help, he received and accepted a job offer from another employer. However, just before starting the new job, General Electric offered him a promotion and matched the new employer’s salary, leading him to remain with his original employer.

    Procedural History

    The case was brought before the U. S. Tax Court to determine the deductibility of the job search fees under IRC § 162(a). The court reviewed similar cases, Primuth and Motto, and applied their rulings to the facts at hand.

    Issue(s)

    1. Whether payments to Chusid for job search services are deductible under IRC § 162(a) as ordinary and necessary expenses incurred in the petitioner’s trade or business.

    Holding

    1. Yes, because the expenses were incurred to continue in the same trade or business of being an engineer, following the court’s precedents in Primuth and Motto.

    Court’s Reasoning

    The court found that the petitioner was in the trade or business of being an engineer, similar to the taxpayers in Primuth and Motto. The court emphasized that the job search expenses were directly related to maintaining this trade or business. The court quoted Primuth, stating, “Once we have made our decision that the petitioner was carrying on a trade or business of being a corporate executive, the problem presented here virtually dissolves for it is difficult to think of a purer business expense than one incurred to permit such an individual to continue to carry on that very trade or business—albeit with a different corporate employer. ” The court rejected the Commissioner’s argument that the case was distinguishable because the new job was not ultimately accepted, noting that the promotion at General Electric was a direct result of the job offer obtained through Chusid’s services.

    Practical Implications

    This decision clarifies that job search expenses are deductible under IRC § 162(a) when incurred to continue in the same trade or business, even if the new job is not taken. Practitioners should advise clients to document such expenses carefully, as they may be deductible. The ruling has implications for how taxpayers approach job searches and the documentation of related expenses. Subsequent cases, such as Morris v. Commissioner, have affirmed this principle. Businesses and taxpayers should be aware of this ruling when considering job transitions and tax planning strategies.

  • Mitchell v. Commissioner, 52 T.C. 170 (1969): Deductibility of Payments Made to Protect Business Reputation

    Mitchell v. Commissioner, 52 T. C. 170 (1969)

    Payments made by an individual to protect their business reputation and avoid litigation can be deductible as ordinary and necessary business expenses under IRC § 162(a), even if related to a securities law violation.

    Summary

    In Mitchell v. Commissioner, the U. S. Tax Court ruled that a payment made by a corporate executive to his employer to settle an alleged violation of Section 16(b) of the Securities Exchange Act was deductible as an ordinary and necessary business expense. William Mitchell, a vice president at General Motors, sold and then purchased company stock within six months, prompting a demand for repayment under Section 16(b). Mitchell paid without admitting liability to avoid damage to his business reputation and potential litigation. The court rejected the Commissioner’s argument that the payment should be treated as a capital loss under the Arrowsmith doctrine, finding instead that Mitchell’s payment was motivated by business reputation concerns, thus qualifying for deduction under IRC § 162(a).

    Facts

    William Mitchell, a vice president at General Motors, sold 2,736 shares of GM stock on October 5, 1962, and reported a capital gain. On January 10, 1963, he exercised a stock option to purchase 2,130 shares. GM later demanded $17,939. 29 from Mitchell, claiming a violation of Section 16(b) of the Securities Exchange Act due to the sale and purchase within six months. Mitchell, advised by counsel, paid the amount to GM without admitting liability, believing it necessary to protect his business reputation and career at GM and to avoid potential litigation and public disclosure in GM’s proxy statement.

    Procedural History

    The Commissioner of Internal Revenue determined a deficiency in Mitchell’s 1963 income tax return, disallowing the deduction of the $17,939. 29 payment as an ordinary business expense and treating it as a long-term capital loss. Mitchell petitioned the U. S. Tax Court for a redetermination of the deficiency.

    Issue(s)

    1. Whether the payment made by Mitchell to General Motors under Section 16(b) of the Securities Exchange Act should be treated as a capital loss under the Arrowsmith doctrine.
    2. Whether the payment constitutes an ordinary and necessary business expense deductible under IRC § 162(a).

    Holding

    1. No, because the payment was not integrally related to the capital gain on the earlier stock sale but was made to protect Mitchell’s business reputation.
    2. Yes, because the payment was made to protect Mitchell’s business reputation, avoid litigation, and prevent embarrassment to himself and GM, making it an ordinary and necessary business expense under IRC § 162(a).

    Court’s Reasoning

    The court found that the Arrowsmith doctrine did not apply because the payment was not directly tied to the earlier capital gain transaction but was instead motivated by Mitchell’s need to protect his business reputation. The court noted that Section 16(b) violations do not inherently have tax consequences and that the payment was not a concession of liability but a proactive measure to avoid negative publicity and potential legal action. The court cited prior cases like Laurence M. Marks and Joseph P. Pike, which supported the deduction of payments made to protect business reputation as ordinary and necessary business expenses. The court emphasized that Mitchell’s belief in the necessity of the payment to protect his reputation was reasonable, supported by the potential for public disclosure and litigation.

    Practical Implications

    This decision clarifies that payments made by individuals to protect their business reputations, even when related to potential legal violations like Section 16(b), can be deductible as ordinary and necessary business expenses under IRC § 162(a). Legal practitioners should advise clients to carefully document the business reasons for such payments, as the court’s ruling hinges on the motivation behind the payment rather than the legal merits of the underlying claim. This case may impact how executives and other professionals approach settlements with employers, emphasizing the importance of protecting one’s professional reputation. Subsequent cases like Vincent E. Oswald and Rev. Rul. 69-115 further support this principle, indicating that the IRS may consider similar payments deductible when made for business reputation protection.